Zitong financial APP learned that Connaught-B (02162) intraday downturn in the afternoon decline widened to 6%, while trading volume significantly increased, the current trading volume is the second highest since its listing in July 21. Recently, Everbright Securities said that considering that the company's R & D investment is likely to continue to increase, it will reduce the company's return net profit by 52% this year. As of press time, Conoya fell 6.03% to HK $22.60, with a turnover of HK $202 million.

Last year, Conoya-B (02162) achieved a revenue of 110 million yuan, a total overall loss of 3.89 billion yuan, and an adjusted net overall loss of 300 million yuan. By the end of 21 years, cash on hand and cash equivalents exceeded 3.5 billion yuan. Huatai then adjusted its target price forecast for the company, based on the DCF valuation method, with a target price of HK $54.85 (previous value: HK $82.97).

At the beginning of this month, Everbright Securities said in its performance review report that in view of the continued abundance of Conoya's products in the research pipeline and the increase in post-clinical products, R & D investment is likely to continue to increase, reducing the 2022-2023 net profit forecast to-5.24 pm-603 million yuan (down 52% by 43% respectively).